ReviewTranslational lung cancer research2026
Next-generation oncolytic virotherapy for lung cancer: bridging innovative vector engineering with clinical immunotherapy.
Review in Translational lung cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lung cancer remains the leading cause of cancer‑related mortality worldwide, with resistance to immune checkpoint inhibitors (ICIs) posing a persistent therapeutic bottleneck for advanced‑stage patients, largely driven by an immunologically "cold" tumor microenvironment (TME). Oncolytic virotherapy has emerged as a paradigm‑shifting strategy to reverse this immunosuppressive phenotype through selective tumor lysis and robust systemic immune ignition. The aim of this review is to offer a comprehensive translational roadmap for oncolytic viruses (OVs) in lung cancer. We systematically dissect the molecular underpinnings of OV‑triggered immunogenic cell death-encompassing apoptosis, necroptosis, and autophagy-as well as their distinct and overlapping contributions to antitumor immunity. Critically, we evaluate major physiological barriers that impede effective systemic OV delivery, including hepatic sequestration, pre‑existing neutralizing antibodies, and tumor stromal obstruction, and showcase cutting‑edge bioengineering countermeasures, such as cell‑mediated carriers, including mesenchymal stem cells and peripheral blood mononuclear cells, extracellular matrix (ECM)‑degrading enzymes, and viruses armed with bispecific T‑cell engagers (BiTEs). We further synthesize the current clinical evidence, providing an updated appraisal of safety profiles, objective response rates, and biomarker‑driven outcomes from clinical trials. By bridging vector engineering innovations with real‑world clinical translation, this review establishes a strategic framework for advancing precision oncolytic immunotherapy in refractory lung cancer.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.